SG11202012902WA - Activators of the unfolded protein response - Google Patents
Activators of the unfolded protein responseInfo
- Publication number
- SG11202012902WA SG11202012902WA SG11202012902WA SG11202012902WA SG11202012902WA SG 11202012902W A SG11202012902W A SG 11202012902WA SG 11202012902W A SG11202012902W A SG 11202012902WA SG 11202012902W A SG11202012902W A SG 11202012902WA SG 11202012902W A SG11202012902W A SG 11202012902WA
- Authority
- SG
- Singapore
- Prior art keywords
- activators
- unfolded protein
- protein response
- response
- unfolded
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693641P | 2018-07-03 | 2018-07-03 | |
| PCT/US2019/040058 WO2020009958A1 (en) | 2018-07-03 | 2019-07-01 | Activators of the unfolded protein response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012902WA true SG11202012902WA (en) | 2021-01-28 |
Family
ID=69059783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012902WA SG11202012902WA (en) | 2018-07-03 | 2019-07-01 | Activators of the unfolded protein response |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20210276951A1 (es) |
| EP (1) | EP3817741A4 (es) |
| JP (1) | JP2021529757A (es) |
| KR (1) | KR20210027382A (es) |
| CN (1) | CN112423743A (es) |
| AU (1) | AU2019299221A1 (es) |
| BR (1) | BR112020025591A2 (es) |
| CA (1) | CA3103958A1 (es) |
| CL (1) | CL2020003423A1 (es) |
| CO (1) | CO2020016690A2 (es) |
| CR (1) | CR20210060A (es) |
| DO (1) | DOP2020000256A (es) |
| EA (1) | EA202190146A1 (es) |
| EC (1) | ECSP20084330A (es) |
| IL (1) | IL279429A (es) |
| JO (1) | JOP20200344A1 (es) |
| MA (1) | MA53105A (es) |
| MX (1) | MX2021000043A (es) |
| PE (1) | PE20210662A1 (es) |
| PH (1) | PH12020552223A1 (es) |
| SG (1) | SG11202012902WA (es) |
| WO (1) | WO2020009958A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3103958A1 (en) | 2018-07-03 | 2020-01-09 | The Board Of Trustees Of The University Of Illinois | Activators of the unfolded protein response |
| WO2021222738A1 (en) * | 2020-05-01 | 2021-11-04 | The Board Of Trustees Of The University Of Illinois | Compounds for estrogen receptor positive cancers |
| WO2022020605A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Treatment of metastasized estrogen receptor positive breast cancer |
| WO2022032146A1 (en) * | 2020-08-07 | 2022-02-10 | Systems Oncology, Llc | Methods for inhibiting growth of era positive cancers |
| MX2023004480A (es) * | 2020-10-23 | 2023-05-04 | Univ Illinois | Compuestos anticancerigenos selectivos para canceres er-positivos. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250442B2 (en) | 2002-03-15 | 2007-07-31 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| EP1718611A4 (en) * | 2004-02-13 | 2009-09-23 | Harvard College | 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US20070299102A1 (en) * | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
| AR056544A1 (es) | 2005-09-29 | 2007-10-10 | Wyeth Corp | Derivados fenilaminopropanol y metodos de uso de los mismos |
| PA8743601A1 (es) | 2006-08-24 | 2009-02-09 | Wyeth Corp | Proceso para preparar derivados de indonelinona fenilaminopropanol |
| WO2008071387A1 (en) * | 2006-12-11 | 2008-06-19 | Topotarget A/S | Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers |
| JP2010525024A (ja) | 2007-04-24 | 2010-07-22 | トポターゲット・アクティーゼルスカブ | 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物 |
| ES2601856T3 (es) | 2007-06-08 | 2017-02-16 | Mannkind Corporation | Inhibidores de la IRE-1A |
| WO2010109008A1 (en) | 2009-03-26 | 2010-09-30 | Topotarget A/S | Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones |
| US20160106711A1 (en) | 2012-09-20 | 2016-04-21 | President And Fellows Of Harvard College | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation |
| US9316631B1 (en) | 2012-10-19 | 2016-04-19 | Whitehead Institute For Biomedical Research | ER-stress inducing compounds and methods of use thereof |
| CA2898732A1 (en) * | 2013-01-18 | 2014-07-24 | Mao CHENGJIAN | Estrogen receptor inhibitors |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| PT3004090T (pt) | 2013-05-28 | 2017-12-22 | Astrazeneca Ab | Compostos químicos |
| CA3103958A1 (en) | 2018-07-03 | 2020-01-09 | The Board Of Trustees Of The University Of Illinois | Activators of the unfolded protein response |
-
2019
- 2019-07-01 CA CA3103958A patent/CA3103958A1/en not_active Abandoned
- 2019-07-01 EA EA202190146A patent/EA202190146A1/ru unknown
- 2019-07-01 BR BR112020025591-2A patent/BR112020025591A2/pt not_active IP Right Cessation
- 2019-07-01 JO JOP/2020/0344A patent/JOP20200344A1/ar unknown
- 2019-07-01 WO PCT/US2019/040058 patent/WO2020009958A1/en active Application Filing
- 2019-07-01 MX MX2021000043A patent/MX2021000043A/es unknown
- 2019-07-01 EP EP19831532.7A patent/EP3817741A4/en not_active Withdrawn
- 2019-07-01 MA MA053105A patent/MA53105A/fr unknown
- 2019-07-01 SG SG11202012902WA patent/SG11202012902WA/en unknown
- 2019-07-01 US US17/254,771 patent/US20210276951A1/en active Pending
- 2019-07-01 JP JP2020573046A patent/JP2021529757A/ja active Pending
- 2019-07-01 PE PE2020002206A patent/PE20210662A1/es unknown
- 2019-07-01 KR KR1020217001833A patent/KR20210027382A/ko unknown
- 2019-07-01 AU AU2019299221A patent/AU2019299221A1/en not_active Abandoned
- 2019-07-01 CR CR20210060A patent/CR20210060A/es unknown
- 2019-07-01 CN CN201980045131.2A patent/CN112423743A/zh active Pending
-
2020
- 2020-02-26 US US16/801,839 patent/US11046647B2/en active Active
- 2020-12-14 IL IL279429A patent/IL279429A/en unknown
- 2020-12-19 PH PH12020552223A patent/PH12020552223A1/en unknown
- 2020-12-29 EC ECSENADI202084330A patent/ECSP20084330A/es unknown
- 2020-12-29 CL CL2020003423A patent/CL2020003423A1/es unknown
- 2020-12-29 DO DO2020000256A patent/DOP2020000256A/es unknown
- 2020-12-30 CO CONC2020/0016690A patent/CO2020016690A2/es unknown
-
2021
- 2021-05-13 US US17/319,447 patent/US11584718B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020009958A1 (en) | 2020-01-09 |
| EA202190146A1 (ru) | 2021-04-27 |
| CN112423743A (zh) | 2021-02-26 |
| US20200190029A1 (en) | 2020-06-18 |
| US20210340100A1 (en) | 2021-11-04 |
| US11584718B2 (en) | 2023-02-21 |
| US20210276951A1 (en) | 2021-09-09 |
| PH12020552223A1 (en) | 2021-06-28 |
| MX2021000043A (es) | 2021-03-25 |
| US11046647B2 (en) | 2021-06-29 |
| DOP2020000256A (es) | 2021-03-15 |
| IL279429A (en) | 2021-01-31 |
| JOP20200344A1 (ar) | 2020-12-31 |
| CL2020003423A1 (es) | 2021-05-14 |
| BR112020025591A2 (pt) | 2021-03-23 |
| CR20210060A (es) | 2021-04-08 |
| EP3817741A1 (en) | 2021-05-12 |
| CA3103958A1 (en) | 2020-01-09 |
| JP2021529757A (ja) | 2021-11-04 |
| EP3817741A4 (en) | 2022-07-06 |
| CO2020016690A2 (es) | 2021-01-18 |
| MA53105A (fr) | 2021-05-12 |
| KR20210027382A (ko) | 2021-03-10 |
| ECSP20084330A (es) | 2021-01-29 |
| AU2019299221A1 (en) | 2021-02-04 |
| PE20210662A1 (es) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201913174PA (en) | Novel protein pores | |
| IL262240A (en) | Human anti-vista antibodies and their use | |
| IL271025A (en) | Multibiotic substances and methods of using them | |
| IL279429A (en) | Reaction activators for unfolded proteins | |
| IL276515A (en) | Antibodies specific to PD-L1 and methods of using them | |
| EP3436476A4 (en) | ANTI-RYK ANTIBODIES AND METHOD FOR USE THEREOF | |
| ZA201906235B (en) | Csf1r-based chimeric proteins | |
| DK3737402T3 (en) | Modificeret protein | |
| GB201620070D0 (en) | Signal transduction modifying protein | |
| IL287601A (en) | Variant cd80 proteins and their uses | |
| IL281088A (en) | FLT3L - based chimeric proteins | |
| EP3585410A4 (en) | VSIG8-BASED CHIMERIC PROTEINS | |
| EP3401324A4 (en) | NEW DOMAIN OF PROTEIN TRANSDUCTION AND USE THEREOF | |
| IL281720A (en) | HMGB1 protein derivatives to remove biofilms | |
| ZA201905544B (en) | Modified haemoglobin proteins | |
| EP3651807A4 (en) | PHOSPHOROTHIOATE CONJUGATED PEPTIDES AND METHOD OF USING THEREOF | |
| EP3649159C0 (en) | FUSION PROTEIN | |
| HUP1700012A2 (en) | Novel proteins and use thereof | |
| ZA202005315B (en) | Novel promoter and use thereof | |
| GB201909710D0 (en) | Proteins | |
| GB2574245B (en) | Determining the arterial structure of the hand | |
| AU2017904606A0 (en) | Protein Barista | |
| UA38273S (uk) | Інтер'єр закладу харчування | |
| UA38263S (uk) | Інтер'єр закладу харчування | |
| UA38260S (uk) | Інтер'єр закладу харчування |